STOXIL
LOE ApproachingNDAOPHTHALMICSOLUTION/DROPS
Approved
Apr 1964
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 9h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
STOXIL is an ophthalmic solution approved in 1964 for eye infections, representing a legacy small-molecule antiviral indicated for ocular use. The exact mechanism of action and specific indications are not documented in current data, suggesting this is an older product with limited contemporary clinical activity. It is administered as topical eye drops.
LOE Approaching
As loss of exclusivity approaches, GSK brand teams face portfolio rationalization decisions and may shift resources toward pipeline assets or combination strategies.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
STOXIL represents a legacy maintenance portfolio asset with minimal career growth trajectory and few linked job openings. Professionals joining this product should expect compliance, regulatory, and operational focus rather than commercial expansion or innovation.
Regulatory Affairs SpecialistProduct Manager (Legacy)
Worked on STOXIL at GSK? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.